摘要:
This invention provides a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject and (ii) a pharmaceutically acceptable carrier. This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier. This invention provides a method for vaccinating a subject against Bacillus anthracis infection comprising administering to the subject a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in the subject and (ii) a pharmaceutically acceptable carrier, in an amount effective to stimulate production of antibodies to Bacillus anthracis spores in the subject, thereby vaccinating the subject against Bacillus anthracis.
摘要:
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要:
Compositions and methods are provided for the treatment of IL-17-type inflammatory demyelinating diseases with inhibitors of granulocyte function, e.g. elastase inhibitors. Diseases of interest include multiple sclerosis, neuromyelitis optica, animal models of such diseases, etc. In some embodiments pharmaceutical formulations comprising an elastase inhibitor in an effective dose for treatment of IL-17-type inflammatory demyelinating disease and a pharmaceutically acceptable excipient are provided. Patients may be classified into subtypes prior to treatment, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.
摘要:
The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.
摘要:
The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.
摘要:
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
摘要:
Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.
摘要:
Methods are provided for the inhibition or prevention of relapses in pre-existing autoimmune disease by decreasing activity or expression of osteopontin in immune cells found in tissues affected by the autoimmune disease. Osteopontin is shown herein to mediate autoimmune relapses and induce a shift to the secondary or progressive stage in autoimmune disease. Osteopontin promotes the survival of activated T cells through regulation of transcription factors, FoxO3a and NF-κB and via the expression of pro-apoptotic proteins.
摘要:
Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of an ordered peptide comprising a repeated motif {SEQ ID NO: 1} [1E2Y3Y4K]n, where n is from 2 to 6. Some specific peptides of interest include those having the sequence {SEQ ID NO:4} EYYKEYYKEYYK. The peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other amino acid residues. For therapy, the peptides may be administered topically or parenterally, e.g. by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. In a preferred embodiment, subcutaneous injection is used to deliver the peptide. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, e.g. immunosuppressants, β-interferon, steroids, etc.
摘要翻译:提供组合物和方法用于治疗脱髓鞘性自身免疫性疾病。 给予治疗剂量的有序肽,其包含重复基序(SEQ ID NO:1)[SEQ ID NO:1] / SEQ ID NO:1 / 其中n为2至6.感兴趣的某些特定肽包括具有序列(SEQ ID NO:4)EYYKEYYYYYYK的那些。 肽可以仅由有序重复组成,或者可以通过加入其它氨基酸残基在任一末端延伸。 对于治疗,肽可以局部或肠胃外给药,例如, 通过在特定部位注射,包括皮下,腹膜内,血管内等或通过电转运进行皮下注射。 在优选的实施方案中,皮下注射用于递送肽。 本发明方法用于预防或治疗目的。 本发明的组合物还可以含有其它治疗活性剂,例如, 免疫抑制剂,β-干扰素,类固醇等
摘要:
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.